BioVaxys Technology Corp. Announces Lifting of Cease Trade Order

VANCOUVER, BC, July 12, 2024 -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: BVAXF), a clinical-stage biopharmaceutical company, has announced the lifting of a failure-to-file cease trade order (FFCTO) issued by the Ontario Securities Commission (OSC) on May 15, 2024. The cease trade order was triggered by a delay in the company's financial filings. Specifically, these included the audited annual financial statements for the fiscal year ending October 31, 2023, management's discussion and analysis for the same period, and interim financial statements for the three months ending January 31, 2024, along with related documents.

The OSC issued the FFCTO under National Policy 11-207 due to the delayed filings. The company has now submitted all the required documents, including the interim financial statements and management's discussion for the six months ending April 30, 2024, as mandated by National Instrument 51-102 Continuous Disclosure Obligations. These filings are accessible through BioVaxys' profile on SEDAR+.

The OSC has confirmed that BioVaxys has met the criteria for revoking the FFCTO, and as of July 11, 2024, the cease trade order is officially lifted.

BioVaxys Technology Corp., based in British Columbia, Canada, focuses on developing innovative immunotherapies using its DPX™ immune-educating technology platform and HapTenix© 'neoantigen' tumor cell construct platform. The company's aim is to enhance treatments for cancers, infectious diseases, and various immunological conditions.

BioVaxys' clinical-stage pipeline features maveropepimut-S, a Phase II clinical development candidate for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum-resistant ovarian cancer. Another key candidate, BVX-0918, is a personalized immunotherapeutic vaccine based on the HapTenix© platform, set to enter Phase I clinical trials in Spain for treating late-stage ovarian cancer.

The company leverages its expertise in tumor immunology to create a unique library of T-lymphocytes and related datasets post-vaccination with its personalized immunotherapeutic vaccines. These resources are utilized with predictive algorithms and other technologies to identify new targetable tumor antigens.

BioVaxys' common shares are traded on the CSE under the symbol "BIOV," the Frankfurt Bourse under "5LB," and in the US under "BVAXF."

James Passin, the Chief Executive Officer of BioVaxys, signed off the announcement with his contact details, emphasizing the company's commitment to transparency and communication with its stakeholders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!